Syncona launches cell-therapy company to combat organ rejection
20th May 2019 07:21
(Sharecast News) - Syncona confirmed on Monday that it has founded a new cell-therapy treatment company, pitching in with £34.0m to fund the new venture in exchange for a 69.3% stake.
Read moreSyncona's Blue Earth reports positive prostate study findings
7th May 2019 07:56
(Sharecast News) - Syncona on Tuesday said its portfolio company Blue Earth Diagnostics had reported positive results from a study into prostate cancer diagnosis.
Read moreSyncona puts £18m into Autolus Therapeutics' US IPO
16th Apr 2019 08:08
(Sharecast News) - Healthcare investment company Syncona said on Tuesday that its portfolio company, Autolus Therapeutics, has confirmed the closing of its previously-announced underwritten public offering in the United States of 4,830,000 American depositary shares (ADS).
Read moreSyncona confirms merger of its Gyroscope and Orbit businesses
11th Apr 2019 08:33
(Sharecast News) - Healthcare investment company Syncona announced the merger of its companies Gyroscope Therapeutics - an ophthalmology company developing genetically defined therapies for retinal diseases - and specialist subretinal therapeutic medical device company Orbit Biomedical on Thursday.
Read moreFTSE 250 movers: Cineworld has a blockbuster, Just Group withers away
14th Mar 2019 15:18
(Sharecast News) - London's FTSE 250 was up 0.63% at 19,300.09 in afternoon trade on Friday, as Cineworld put in a blockbuster performance to send the index reeling upwards.
Read moreSyncona focuses short-term cash on more conservative investments
12th Mar 2019 08:28
(Sharecast News) - Healthcare firm Syncona plans to focus its investment strategy more towards conservative investments like cash and bonds moving forward.
Read moreSyncona to cash in as Biogen acquires Nightstar
4th Mar 2019 09:08
(Sharecast News) - Healthcare investment company Syncona updated the market on Nightstar Therapeutics on Monday, confirming it has reached an agreement to be acquired by Biogen at a price of $25.50 per share.
Read moreSyncona pours £21m into immuno-oncology company Anaveon
26th Feb 2019 11:58
(Sharecast News) - Syncona announced a CHF 28m (£21.4m) commitment to Anaveon, a new immuno-oncology company, in a CHF 35m Series A financing on Tuesday, alongside the Novartis Venture Fund.
Read moreSyncona close to injecting funds in new prospects
13th Feb 2019 08:29
(Sharecast News) - Syncona, the healthcare investor, said it was in the "final stages" of agreeing funding for two new companies, though its net asset value dipped in the past quarter.
Read moreAutolus reports early progress with cancer drugs
3rd Dec 2018 07:53
(Sharecast News) - Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Read moreAutolus reports early progress with cancer drugs
3rd Dec 2018 07:53
(Sharecast News) - Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Read moreSyncona grew net asset value 31% in first half
21st Nov 2018 11:13
(Sharecast News) - Life sciences investment fund Syncona saw net asset value increase in first six months of the year, as it confirmed it was on track to meet full-year investment guidance.
Read moreSyncona cheers positive test results for investee Nightstar Therapeutics
24th Sep 2018 08:46
(Sharecast News) - Healthcare investment company Syncona updated the market on its portfolio company Nightstar Therapeutics on Monday, which reported positive proof-of-concept data from the dose escalation study in the XIRIUS trial for NSR-RPGR in XLRP patients.
Read moreSyncona pleased with portfolio performance in latest quarter
9th Aug 2018 11:03
(Sharecast News) - Healthcare company Syncona issued its quarterly update for the three months to 30 June on Thursday, reporting an increase in net assets increased to £1.28bn, or 193.1p per share, for a total return of 23%.
Read moreSmall caps round-up: Imaginatik, Braveheart, Healthcare Locums...
29th Feb 2012 14:19
Imaginatik has signed a new annual contract with a leading provider of healthcare services and medical research in the US. The contract has an initial start-up phase worth $0.12m in the current calendar year, followed by an ongoing annual contract worth $0.15m a year, with Imaginatik supplying it
Read more